University of Groningen
Mastocytosis van Anrooij, Bjorn
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van Anrooij, B. (2019). Mastocytosis: A disease at the crossroads of hematology and allergology. University of Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Mastocytosis: a disease at the
crossroads of hematology and
allergology
Phd thesis
to obtain the degree of PhD at the University of Groningen
on the authority of the Rector Magnificus prof. E. Sterken
and in accordance with
the decision by the College of Deans. This thesis will be defended in public on Wednesday 22 May 2019 at 12.45 hours
by
Bjorn van Anrooij
born on 28 September 1990 in Heerenveen
[2]
Supervisor
Prof. J.C. Kluin-Nelemans
Co-supervisor
Prof. J.N.G. Oude Elberink
Assessment Committee
Prof. E. Didier Prof. W. Timens Prof. A.E.J. Dubois
[3]
Table of contents
Chapter 1____________________________________________________ 5
Introduction
Chapter 2___________________________________________________19
Scope of the thesis
Chapter 3___________________________________________________23
Patient reported disease specific quality of life and symptom severity in systemic mastocytosis
Allergy,71,1585-1593 (2016)
Chapter 4:__________________________________________________ 49
Identification of biological and pharmaceutical mast cell‐ and basophil-related targets
Scandinavian Journal of Immunology,83, 465–472(2016)
Chapter 5:__________________________________________________ 67
Midostaurin in indolent systemic mastocytosis patients: an open-label phase 2 trial
J Allergy Clin Immunol. 14, 1006-1008 (2018)
Chapter 6:__________________________________________________ 91
fatal anaphylaxis to yellow jacket stings in mastocytosis: options for identification and treatment of at-risk patients
J Allergy Clin Immunol Pract. 2017:1264-1271.
Chapter 7:_________________________________________________ 115
higher mast cell load lowers risk of hymenoptera venom anaphylaxis in mastocytosis
J Allergy Clin Immunol. 2013 Jul;132(1):125-30
Chapter 8__________________________________________________135
CD30 in systemic mastocytosis
Supervisor
Prof. J.C. Kluin-Nelemans
Co-supervisor
Prof. J.N.G. Oude Elberink
Assessment Committee
Prof. E. Didier Prof. W. Timens Prof. A.E.J. Dubois
Table of contents
Chapter 1____________________________________________________ 5
Introduction
Chapter 2___________________________________________________19
Scope of the thesis
Chapter 3___________________________________________________23
Patient reported disease specific quality of life and symptom severity in systemic mastocytosis
Allergy,71,1585-1593 (2016)
Chapter 4:__________________________________________________ 49
Identification of biological and pharmaceutical mast cell‐ and basophil-related targets
Scandinavian Journal of Immunology,83, 465–472(2016)
Chapter 5:__________________________________________________ 67
Midostaurin in indolent systemic mastocytosis patients: an open-label phase 2 trial
J Allergy Clin Immunol. 14, 1006-1008 (2018)
Chapter 6:__________________________________________________ 91
fatal anaphylaxis to yellow jacket stings in mastocytosis: options for identification and treatment of at-risk patients
J Allergy Clin Immunol Pract. 2017:1264-1271.
Chapter 7:_________________________________________________ 115
higher mast cell load lowers risk of hymenoptera venom anaphylaxis in mastocytosis
J Allergy Clin Immunol. 2013 Jul;132(1):125-30
Chapter 8__________________________________________________135
CD30 in systemic mastocytosis
[4]
Chapter 9__________________________________________________159
Soluble CD30 reflects mast cell load and hymenoptera anaphylaxis risk in mastocytosis
in preparation
Chapter 10_________________________________________________181
Summary and future perspectives
Chapter 11_________________________________________________195 Apendixes Nederlands samenvatting ____________________________________196 Dankwoord ________________________________________________201 Curriculum Vitae____________________________________________206 List of publications___________________________________________207 [5]
![[Review of: M.I. Santiago (2006) The ecology of oil: Environment, labor, and the Mexican Revolution, 1900-1938] - 300975](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==)